Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-07-17, Stock:NVS, The news for the past five days is as follows:
2019-07-10: NEWS1: Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill.NEWS2: EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply.NEWS3: EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply.NEWS4: How This Novartis Mashup Could Validate A Biotech Company's Cancer Drug.NEWS5: The 10 Biggest Healthcare Stocks.NEWS6: The 10 Biggest Healthcare Stocks.NEWS7: The 10 Biggest Healthcare Stocks.NEWS8: Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset.NEWS9: Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset.NEWS10: EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply.NEWS11: Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset.NEWS12: Here's Why Array BioPharma Soared 75.4% in June.NEWS13: Here's Why Array BioPharma Soared 75.4% in June.NEWS14: Mylan Falls on Report That EpiPen Shortage Is Hurting Patients and Pharmacists.NEWS15: The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV.NEWS16: Aerie Completes Enrollment Under Rhopressa Study in Japan.NEWS17: Aerie Completes Enrollment Under Rhopressa Study in Japan.NEWS18: Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline.NEWS19: Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline.NEWS20: Bayer-J&J Announce Positive Xarelto Data in Children with VTE.NEWS21: Bayer-J&J Announce Positive Xarelto Data in Children with VTE.NEWS22: Novo Nordisk Reports Encouraging Data From Hemophilia Studies.NEWS23: Novo Nordisk Reports Encouraging Data From Hemophilia Studies.
2019-07-11: NEWS1: Amneal (AMRX) Down on Guidance Update & Restructuring Plan.NEWS2: Amneal (AMRX) Down on Guidance Update & Restructuring Plan.NEWS3: Amgen and Novartis drop Alzheimer's-prevention study after patients worsened.NEWS4: Signature Select Canadian Fund's Top 6 Buys.NEWS5: Amneal (AMRX) Down on Guidance Update & Restructuring Plan.NEWS6: Amgen, Novartis abandon two Alzheimer’s drug studies.NEWS7: Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill.NEWS8: Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill.
2019-07-12: NEWS1: What Happened in the Stock Market Today.NEWS2: What Happened in the Stock Market Today.NEWS3: Here's Why NeoGenomics Stock Rose 74% in the First Half of the Year.NEWS4: Here's Why NeoGenomics Stock Rose 74% in the First Half of the Year.NEWS5: What Happened in the Stock Market Today.NEWS6: Aimmune Down on Negative ICER Review on Allergy Candidate.NEWS7: Aimmune Down on Negative ICER Review on Allergy Candidate.NEWS8: Amgen & Novartis' Alzheimer Studies End in Another Failure.NEWS9: Amgen & Novartis' Alzheimer Studies End in Another Failure.NEWS10: Amgen & Novartis' Alzheimer Studies End in Another Failure.NEWS11: Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug.NEWS12: Aimmune Down on Negative ICER Review on Allergy Candidate.NEWS13: Dow Jones Futures: Illumina, Profitable Marijuana Stock Tumble; Amgen-Novartis Alzheimer's Drug Fails.NEWS14: The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study.
2019-07-15: NEWS1: J&J Falls Amid Reports of Criminal Probe Into Talcum Powder.NEWS2: J&J Falls Amid Reports of Criminal Probe Into Talcum Powder.NEWS3: J&J Falls Amid Reports of Criminal Probe Into Talcum Powder.
2019-07-16: NEWS1: Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?.NEWS2: Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?.NEWS3: Should You Pick Up Novartis (NVS) Before Q2 Earnings?.NEWS4: Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?.NEWS5: Eisai boosts focus on Alzheimer's with new research facility, funding.NEWS6: Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA.NEWS7: Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA.NEWS8: Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall.NEWS9: Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall.NEWS10: Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA.NEWS11: Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall.

Answer: Rise